Peptide Quality Control: What to Check Beyond Purity

The Conventional View on Peptide Quality Control Is Purity Percentage

Peptide quality control, in most purchasing conversations, means one number: the purity figure on the certificate of analysis, usually written as “>95%”. The logic is straightforward. A higher percentage means a cleaner product, and a cleaner product is a better one.

Bachem’s published grade ladder is the clearest expression of that logic. The company’s quality control guide for amino acids and peptides recommends >95% purity for NMR, crystallography and use as a reference in quantitative enzyme-substrate, receptor-ligand and blocking studies; 90-95%for monoclonal antibody production and quantitative in vivo or in vitro work;>80% for qualitative Western blotting and phosphorylation studies; and Immunograde (>65%) for polyclonal antibody production.

That is a defensible framework for matching a product to an application. It is also, in practice, the only criterion many buyers apply.

Key Takeaway: The purity shorthand is a vendor grade convention, not a regulatory requirement.

Where the purity shorthand came from

The grade tiers originated in vendor catalogues and their price ladders, not in any pharmacopoeial monograph. No monograph requires a single headline purity number as the basis of a purchase decision, which is why research-grade peptide purity testing has to be judged against the method behind the figure rather than the figure alone.

Why Purity Percentage Alone Fails as a Peptide Quality Control Criterion

A purity figure is not a property of the material. It is an area percentage produced by one specific method run under one specific set of conditions, and that distinction is where most peptide quality control arguments quietly fall apart.

Problem 1: the number is method-defined. A bare “>95%” tells you nothing about the column chemistry and dimensions, the mobile phase and gradient, the flow rate, injection volume, detection wavelength, run time, integration rules, or whether the solvent front was excluded. Change any of those and the same vial can produce a different figure. Two labs reporting different purity for one batch is not necessarily a dispute about the material; it can be a dispute about the method. Any research-grade peptide purity testing result that arrives without those parameters is not reproducible, and a result you cannot reproduce is not a specification.

Problem 2: mass identity is not purity. LC-MS confirms accurate molecular mass coupled with chromatographic separation, and MALDI-TOF delivers fast intact-mass fingerprinting. But MALDI-TOF is weak on complex mixtures, where matrix peaks, salt and adduct effects, and ion suppression interfere, and it gives limited sequence information. MS/MS supplies fragment-ion sequence information and can localize modifications, while peptide mapping provides digest-based sequence coverage but can miss partial coverage and labile modifications. None of these methods reliably quantifies relative composition. Accurate mass alone cannot resolve every isobaric or isomeric pair (peptide characterization methods, retrieved 2026-05-11).

Problem 3: purity does not detect the contaminants that actually harm. USP <71> sterility testing covers viable microorganisms only. It does not detect endotoxin, residual solvents, or residual TFA, and an HPLC purity figure does not detect most of them either. Those are separate tests with separate specifications, which is why purchasable QC packages state them separately: endotoxin guaranteed at ≤0.01 EU/µg and TFA reduced to <10%, as low as <1% (GenScript AccuPep+QC). A purity percentage is silent on all of it.

There is a fourth layer that compounds the first three. Net peptide content is not purity: NPC measures peptide relative to non-peptidic material, mostly counterions and moisture, while purity includes peptidic contaminants, so the two are not equivalent. Low NPC is expected for basic-amino-acid-rich and hydrophilic peptides even at high purity, and purity itself varies batch to batch, with a peptide ordered at 80% potentially delivering anywhere from 80% to 100% (Bachem QC guide).

The EMA’s synthetic peptide guideline, effective June 2026, treats impurity control as something that must be “scientifically justified by batch data, not merely aligned to a theoretical threshold value,” and splits peptide-related impurities into specified identified, specified unidentified, unspecified, and total categories rather than collapsing them into one figure (EMA synthetic peptide guideline, retrieved 2026-06-14).

Taken together, the three problems point the same way: a purity percentage answers a much narrower question than most buyers believe it answers. It describes one method’s view of one dimension of the material, and it is silent on identity, on sequence, on counterions, on moisture, and on the contaminants that carry the actual risk.

What the Data Actually Shows About Peptide Quality Control Failures

The documented failures are identity, labelling and contaminant failures, not marginal purity shortfalls. In 2026, Victoria’s Chief Health Officer linked six cases of acute liver toxicity to unapproved peptide products labelled Retatrutide, noting the clinical presentation suggested “additional contaminants may be contributing” (RACGP newsGP, 22 June 2026). By late August, seven Victorian patients had been hospitalised for acute liver toxicity after using a counterfeit of retatrutide, and Canberra Health Services reported liver damage without releasing a count (ABC News, 24 August 2026). In both reports the contaminant cause is stated as a hypothesis, not a confirmed finding.

सेवाहरू Labelling failures are documented separately. The FDA records compounded products carrying false label information, including labels naming pharmacies that never compounded the product, and notes that salt forms such as semaglutide sodium and semaglutide acetate “are different active ingredients than those used in approved drugs” (FDA, updated 9 January 2026).

Read together, these point to five criteria that peptide quality control should actually test: identity confirmation, purity testing with a declared method, peptide impurity profiling, labelling accuracy, and peptide supply chain traceability. Each one has to be evidenced by a specific document field, not by an assertion.

Reading the enforcement record without overreading it

The enforcement counts circulating online need scope. Public Citizen’s June 2026 analysis counted 14 FDA warning letters sent since December 2024 to companies selling retatrutide, and found that as of May 2026, 11 of the 14 continued advertising retatrutide or other unapproved peptides while 8 continued selling retatrutide (Public Citizen, 16 June 2026). That review is the advocacy organisation’s own, and the letters were not independently recounted.

The same analysis cites Finnrick, a commercial testing service, for 2,759 samples of retatrutide tested since December 2024, of which 71 of 179 vendors (39.6%) were rated “poor,” “bad,” or “fraud” (Public Citizen, 16 June 2026). Finnrick’s business model depends on distrust of vendors, its sampling is not randomised, and the assay behind the ratings is unspecified. Figures of this type vary by source; the direction of the finding is more reliable than any single number.

Identity Confirmation Is the First Peptide Quality Control Test That Matters

पेप्टाइड संश्लेषण Identity confirmation is the test that would have caught the TGA case, because the vial Shop contained a different molecule entirely. Purity percentage cannot detect that: a mislabelled or substituted peptide can still return a clean single-peak chromatogram.

The practical bar is accurate molecular mass by LC-MS with chromatographic separation, plus orthogonal confirmation by MS/MS fragmentation or peptide mapping for sequence-level coverage. Each method has blind spots worth knowing before you rely on it. MALDI-TOF spectra can carry matrix peaks, salt and adduct effects, and ion suppression that shift or mask the true mass. Peptide mapping can miss partial sequence coverage and labile modifications.

Pro Tip: The peptide certificate of analysis should name the method used, report observed versus theoretical सिंथेटिक पेप्टाइड्स mass, and state the sequence coverage achieved. If any of those three fields is missing, the identity claim is not checkable.

Purity Testing and Impurity Profiling Under the Current Peptide Quality Control Framework

Purity testing and peptide impurity profiling are two separate tests with separate acceptance logic, and the current framework sets the impurity thresholds rather than leaving them to the supplier. The EMA’s synthetic-peptide guideline, effective 1 June 2026, sets reporting, identification and qualification thresholds at >0.1%, >0.5% and >1.0% respectively, and states that ICH Q3A/Q3B do not apply to synthetic peptides (EMA guideline on the development and manufacture of synthetic peptides, published 9 December 2025). Those figures reached this article through a secondary summary whose own text says they should be confirmed against the primary guideline, and the primary PDF could not be read here, so treat them as a working reference and check the source document directly before you write them into a specification.

Impurity control is anchored to the Ph. Eur. general monograph “Substances for Pharmaceutical Use”, and the guideline requires it to be scientifically justified by batch data rather than aligned to a theoretical threshold. That distinction matters when you read a certificate of analysis: the categories are specified identified, specified unidentified, unspecified and total, and a single “purity” figure collapses all four.

Non-peptide contaminants sit outside that table and need their own tests. Endotoxin is measured by USP <85> / LAL, sterility by USP <71>, residual solvents by headspace GC against ICH Q3C, the TFA counterion by ion chromatography, CE or ¹⁹F NMR, counterion identity by ion chromatography, and moisture by Karl Fischer titration. Commercial specifications are published, for example by GenScript, with endotoxin at ≤0.01 EU/µg and TFA held below 10%, down to below 1% for some grades.

One more number belongs in the same conversation: net peptide content is not purity. Low NPC is expected for basic and hydrophilic peptides even at high purity, and Bachem’s QC guide notes the batch-to-batch variability this creates, so both figures have to be considered when you prepare a solution.

Labelling and Traceability Complete the Peptide Quality Control Package

Peptide supply chain traceability is the criterion that makes every other test auditable, and it is the one buyers skip most often. A purity figure, an identity result and an impurity profile are only as good as the record that ties them to a specific vial.

A receiving record should capture the lot number, supplier identity, date received, vial condition, shipping and storage conditions, and the version of the peptide certificate of analysis the shipment was matched against. The TGA’s September 2026 safety alert states that products supplied in unmarked vials, purchased online or obtained from overseas, are not subject to the same controls over the quality or efficacy of the goods when compared with medicines approved for supply in Australia.

Records built this way follow the ALCOA expectation: attributable, legible, contemporaneous, original and accurate.

⚠️ Warning: A CoA that cannot be matched to a lot number and a receiving record is not traceability.

How to Apply This Peptide Quality Control Framework

Start with the lot, not the catalogue. Before you place an order, ask the supplier for the full analytical and documentation package for the specific lot you would receive, and treat the catalogue purity figure as marketing until that package arrives.

1. Request the peptide certificate of analysis with method parameters. Ask for the chromatogram, the peak table, and the column, gradient and detection wavelength behind them. Quick win: same day.

2. Check identity evidence. Confirm the package reports observed versus theoretical mass and states sequence coverage. Quick win.

3. Check impurity reporting. Ask which thresholds the supplier applies for reporting, identifying and qualifying impurities, and whether batch-to-batch variability is described. Longer-term.

4. Confirm the non-peptide panel. Endotoxin, sterility, residual solvents, counterion and moisture should be reported where your intended use requires them. Commercial QC specifications are published, and GenScript’s peptide quality control specifications illustrate the documented bar, including endotoxin limits and residual TFA ranges. Longer-term.

5. Verify traceability. Match lot number, label and receiving record. Quick win.

A complete package for one lot typically contains the CoA with method parameters, a representative chromatogram and peak table, identity data, impurity results against stated thresholds, the applicable non-peptide panel, and a lot number that matches the label and your receiving record. Bachem’s quality control guide describes how batch-to-batch variability and non-peptide content are handled, which is the level of detail worth asking for. MOL Changes supports this workflow by assembling analytical and lot documentation into a single reviewable package.

Measure two things: the proportion of lots arriving with a complete package, and the rate of discrepancies between the label and the CoA. Expect the first supplier comparisons to be decisive within one or two procurement cycles.

Caveats on This Peptide Quality Control Argument

The strongest objection to this framework is that the trigger evidence is thin. The TGA’s September 2026 safety alert rests on laboratory testing of a single labelled-retatrutide vial, with no replicate count reported, and the RACGP’s clinical news coverage of the Victorian case clusters describes the contaminant cause as a hypothesis rather than a lab-confirmed finding.

Two things this research does not establish deserve stating plainly. No source here gives a verified purity percentage measured on a retatrutide-labelled retail sample, and no source gives a verified rate of end-user certificate-of-analysis forgery. The prevalence of the problem is unproven.

The conventional view also still holds in places. For early-stage qualitative work such as Western blotting, a lower-grade material with a documented method may be entirely adequate, and Bachem’s QC guide grade tiers remain a reasonable starting heuristic when the intended use is qualitative.

That is why the case for this peptide quality control framework is not scale. It is checkability: every criterion here can be verified against a document you already receive. पेप्टाइड उत्पादन

But doesn’t a higher purity grade solve this?

छैन, because a grade tier and an identity test answer different questions. A purity grade tells you how much of the material in the vial is the stated compound; it does not tell you that the stated compound is the one in the vial. The TGA’s September 2026 safety alert described an identity failure, and no purity grade would have detected a different molecule (TGA safety alert). Use both: a grade tier as a starting filter, identity confirmation as the test that actually closes the gap.

What if I have already qualified a supplier on purity alone?

Nothing you have already bought needs to be discarded, and the qualification does not have to start over. Re-baseline the relationship instead: ask the supplier for the method-level documentation behind the lots you have already received, meaning the chromatographic method parameters and the chromatogram that produced the purity figure on the peptide certificate of analysis, not a reissued certificate with the same number on it.

That request is the whole transition, and the response is the finding. A supplier that cannot produce method parameters and a chromatogram for a past lot has told you something about how that lot was qualified, and about what the documentation will look like for the next one.

How do you respond to the argument that these standards are for pharmaceutical manufacture, not research use?

The thresholds are written for pharmaceutical development, and that scope is real. The EMA guideline on synthetic peptides that took effect in June 2026 addresses manufacturers developing medicinal products, not suppliers selling research-grade material. But the mechanism it relies on transfers cleanly: the guideline asks manufacturers to justify their control strategy with batch data rather than to clear a blanket threshold. That is the same discipline a research buyer applies when scaling peptide impurity profiling to intended use, testing identity and the impurities that matter for the experiment instead of adopting the full pharmaceutical panel wholesale.

Conclusion: A Documentation Standard, Not a Scare

The retatrutide warning is best read as a documentation failure, not a purity failure, and the fix is a five-criterion package (identity confirmation, purity testing, impurity profiling, labelling, and traceability) rather than a higher purity number. That reframing matters because it changes what buyers ask for. Instead of requesting a better grade, purchasers can make method parameters, chromatograms, and lot records a condition of purchase, which makes suppliers who cannot produce them visibly distinguishable from those who can. The shift is already underway in adjacent regulated markets, where documentation completeness, not a headline percentage, separates qualified suppliers from unqualified ones.

If that standard becomes routine, a peptide certificate of analysis stops being a marketing artifact and becomes a checkable record: a document a reviewer can audit, not a number a buyer has to trust. That is the future state worth working toward, and it does not require new regulation to start. It requires buyers to ask better questions before they order.

Next steps: Request a documentation package before your next peptide order. Ask for the method parameters behind the purity figure, the chromatogram it came from, and the lot record that ties the material to its test results. A supplier who can produce all three is a supplier you can qualify on evidence rather than on a number.

Disclosure: MOL Changes provides peptide synthesis and quality documentation services, and has a commercial interest in the documentation standards described in this article.